{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:30:08Z","timestamp":1790289008880,"version":"4.1.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04896-8","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:06:53Z","timestamp":1778591213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the GSK-3\u03b2\/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities"],"prefix":"10.1007","volume":"96","author":[{"given":"Marwan","family":"Al-Hajeili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"El-Saber Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"4896_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bpobgyn.2020.12.001","volume":"74","author":"C Lok","year":"2021","unstructured":"Lok C, Frijstein M, van Trommel N (2021) Clinical presentation and diagnosis of Gestational Trophoblastic Disease. Best Pract Res Clin Obstet Gynecol 74:42\u201352. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.12.001","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"key":"4896_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.placenta.2016.12.009","volume":"50","author":"JBH de Mello","year":"2017","unstructured":"de Mello JBH, Ramos Cirilo PD, Michelin OC, Cust\u00f3dio Domingues MA, Cunha Rudge MV, Rogatto SR, Maest\u00e1 I (2017) Genomic profile in gestational and non-gestational choriocarcinomas. Placenta 50:8\u201315. https:\/\/doi.org\/10.1016\/j.placenta.2016.12.009","journal-title":"Placenta"},{"key":"4896_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/1471-0528.16202","volume":"127","author":"P Savage","year":"2020","unstructured":"Savage P, Winter M, Parker V, Harding V, Sita-Lumsden A, Fisher RA, Harvey R, Unsworth N, Sarwar N, Short D, Aguiar X, Tidy J, Hancock B, Coleman R, Seckl MJ (2020) Demographics, natural history and treatment outcomes of non\u2010molar gestational choriocarcinoma: a UK population study, BJOG. Int J Obstet Gynecol 127:1102\u20131107. https:\/\/doi.org\/10.1111\/1471-0528.16202","journal-title":"Int J Obstet Gynecol"},{"key":"4896_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tjog.2015.05.011","volume":"56","author":"M Mangla","year":"2017","unstructured":"Mangla M, Singla D, Kaur H, Sharma S (2017) Unusual clinical presentations of choriocarcinoma: A systematic review of case reports. Taiwan J Obstet Gynecol 56:1\u20138. https:\/\/doi.org\/10.1016\/j.tjog.2015.05.011","journal-title":"Taiwan J Obstet Gynecol"},{"key":"4896_CR5","doi-asserted-by":"publisher","unstructured":"Ostreni I, Colatosti A, Basile EJ, Rafa O (2022) Elevated Beta-Human Chorionic Gonadotropin in a Non-pregnant Female With Altered Kidney Function, Cureus https:\/\/doi.org\/10.7759\/cureus.23747","DOI":"10.7759\/cureus.23747"},{"key":"4896_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.5858\/arpa.2019-0207-oa","volume":"144","author":"RD Whaley","year":"2019","unstructured":"Whaley RD, Dougherty RE, Cheng L, Ulbright TM (2019) Fluorescence In Situ Hybridization for the X and Y Chromosome Centromeres Helps Differentiate Between Gestational and Nongestational Choriocarcinoma in Clinically Ambiguous Cases. Arch Pathol Lab Med 144:863\u2013868. https:\/\/doi.org\/10.5858\/arpa.2019-0207-oa","journal-title":"Arch Pathol Lab Med"},{"key":"4896_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737159.2025.2453506","volume":"25","author":"KA Rozenova","year":"2025","unstructured":"Rozenova KA, Buza N, Hui P (2025) Gestational trophoblastic disease: STR genotyping for precision diagnosis. Expert Rev Mol Diagn 25:1\u201319. https:\/\/doi.org\/10.1080\/14737159.2025.2453506","journal-title":"Expert Rev Mol Diagn"},{"key":"4896_CR8","doi-asserted-by":"publisher","unstructured":"Hammond CB, Soper JT, Diseases GT (2008) The Global Library of Women\u2019s Medicine https:\/\/doi.org\/10.3843\/GLOWM.10263","DOI":"10.3843\/GLOWM.10263"},{"key":"4896_CR9","doi-asserted-by":"publisher","first-page":"643e1","DOI":"10.1016\/j.ajog.2009.03.011","volume":"200","author":"GE Chalouhi","year":"2009","unstructured":"Chalouhi GE, Golfier F, Soignon P, Massardier J, Guastalla JP, Trillet-Lenoir V, Schott AM, Raudrant D (2009) Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. Am J Obstet Gynecol 200:643e1\u201364643. https:\/\/doi.org\/10.1016\/j.ajog.2009.03.011","journal-title":"Am J Obstet Gynecol"},{"key":"4896_CR10","unstructured":"PDQ Adult Treatment Editorial Board, Gestational Trophoblastic Disease Treatment (PDQ\u00ae): Health Professional Version, PDQ Cancer Information Summaries (2002) https:\/\/www.cancer.gov\/types\/gestational-trophoblastic\/hp\/gtd-treatment-pdq (accessed April 5, 2026)"},{"key":"4896_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0090-8258(88)80029-5","volume":"31","author":"G Bolis","year":"1988","unstructured":"Bolis G, Bonazzi C, Landoni F, Mangili G, Vergadoro F, Zanaboni F, Mangioni C (1988) EMA\/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 31:439\u2013444. https:\/\/doi.org\/10.1016\/S0090-8258(88)80029-5","journal-title":"Gynecol Oncol"},{"key":"4896_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0020-7292(02)00063-2","volume":"77","author":"Figo Oncology Committee, FIGO staging for gestational trophoblastic neoplasia 2000","year":"2002","unstructured":"Figo Oncology Committee, FIGO staging for gestational trophoblastic neoplasia 2000 (2002) FIGO Oncology Committee. Int J Gynecol Obstet 77:285\u2013287. https:\/\/doi.org\/10.1016\/S0020-7292(02)00063-2","journal-title":"Int J Gynecol Obstet"},{"key":"4896_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/GCO.0000000000000674","volume":"33","author":"JJ Clark","year":"2021","unstructured":"Clark JJ, Slater S, Seckl MJ (2021) Treatment of Gestational Trophoblastic Disease in the 2020s. Curr Opin Obstet Gynecol 33:7. https:\/\/doi.org\/10.1097\/GCO.0000000000000674","journal-title":"Curr Opin Obstet Gynecol"},{"key":"4896_CR14","doi-asserted-by":"publisher","unstructured":"Hassan AR, Itsura P, Rosen BP, Covens A, Shaffi AF, Odongo EB, Mburu AW, Smith WL, Moturi SK, Too RK, Ayeah CM, Tonui P (2024) Mortality Factors in High and Ultra-High-Risk Gestational Trophoblastic Neoplasia at Moi Teaching & Referral Hospital: A Decade-Long Observation in Kenya. https:\/\/doi.org\/10.2139\/SSRN.4695730","DOI":"10.2139\/SSRN.4695730"},{"key":"4896_CR15","doi-asserted-by":"publisher","first-page":"CD008891","DOI":"10.1002\/14651858.CD008891.PUB3","volume":"2016","author":"M Alazzam","year":"2016","unstructured":"Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA (2016) Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2016:CD008891. https:\/\/doi.org\/10.1002\/14651858.CD008891.PUB3","journal-title":"Cochrane Database Syst Rev"},{"key":"4896_CR16","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1080\/14767058.2018.1531843","volume":"33","author":"N Lavu","year":"2019","unstructured":"Lavu N, Richardson L, Bonney E, Menon R (2019) Glycogen synthase kinase (GSK) 3 in Pregnancy and Parturition: a Systematic Review of Literature. J Matern Fetal Neonatal Med 33:1946. https:\/\/doi.org\/10.1080\/14767058.2018.1531843","journal-title":"J Matern Fetal Neonatal Med"},{"key":"4896_CR17","doi-asserted-by":"publisher","first-page":"108727","DOI":"10.1016\/j.ejso.2024.108727","volume":"51","author":"G Camilleri","year":"2025","unstructured":"Camilleri G, Calleja-Aguis J, Said E (2025) Trophoblastic disease and choriocarcinoma. Eur J Surg Oncol 51:108727. https:\/\/doi.org\/10.1016\/j.ejso.2024.108727","journal-title":"Eur J Surg Oncol"},{"key":"4896_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/oalib.1109923","volume":"10","author":"MAF Amalina","year":"2023","unstructured":"Amalina MAF, Wang SM, AL-Naggar RA, Thanikasalam K (2023) Epidemiol Gestation Choriocarcinoma: Syst Rev OAlib 10:1\u201311. https:\/\/doi.org\/10.4236\/oalib.1109923","journal-title":"Epidemiol Gestation Choriocarcinoma: Syst Rev OAlib"},{"key":"4896_CR19","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.18203\/2320-1770.ijrcog20203824","volume":"9","author":"F Al Wahaibi","year":"2020","unstructured":"Al Wahaibi F, Gowri V, Al Kharusi S, Al T, Rawahi (2020) Prevalence of gestational choriocarcinoma in a parous population in ten years. Int J Reprod Contracept Obstet Gynecol 9:3537. https:\/\/doi.org\/10.18203\/2320-1770.ijrcog20203824","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"4896_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4103\/ijmr.ijmr_2585_19","volume":"152","author":"S Singhal","year":"2020","unstructured":"Singhal S, Kumar L, Kumar S, Khurana S, Bhatla N (2020) Predictors of chemotherapy resistance & relapse in gestational trophoblastic neoplasia. Indian J Med Res 152:595\u2013606. https:\/\/doi.org\/10.4103\/ijmr.ijmr_2585_19","journal-title":"Indian J Med Res"},{"key":"4896_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejogrb.2020.05.046","volume":"251","author":"H Yu","year":"2020","unstructured":"Yu H, Li J, Zhu T, Xue X, Lu X (2020) Evaluation and influence of lung metastasis on patient outcome in gestational trophoblastic neoplasia: A 10-year study at a single institution. Eur J Obstet Gynecol Reproductive Biology 251:162\u2013166. https:\/\/doi.org\/10.1016\/j.ejogrb.2020.05.046","journal-title":"Eur J Obstet Gynecol Reproductive Biology"},{"key":"4896_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/s1470-2045(21)00262-x","volume":"22","author":"A Braga","year":"2021","unstructured":"Braga A, Paiva G, Ghorani E, Freitas F, Velarde LGC, Kaur B, Unsworth N, Lozano-Kuehne J, dos Santos Esteves APV, Rezende Filho J, Amim J, Aguiar X, Sarwar N, Elias KM, Horowitz NS, Berkowitz RS, Seckl MJ (2021) Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol 22:1188\u20131198. https:\/\/doi.org\/10.1016\/s1470-2045(21)00262-x","journal-title":"Lancet Oncol"},{"key":"4896_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejca.2021.11.004","volume":"161","author":"F Jiang","year":"2022","unstructured":"Jiang F, Lin J-K, Xiang Y, Xu Z, Wan X-R, Feng F-Z, Ren T, Yang J-J, Zhao J (2022) The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study. Eur J Cancer 161:119\u2013127. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.004","journal-title":"Eur J Cancer"},{"key":"4896_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2021.02.005","volume":"74","author":"B Kaur","year":"2021","unstructured":"Kaur B (2021) Pathology of gestational trophoblastic disease (GTD). Best Pract Res Clin Obstet Gynecol 74:3\u201328. https:\/\/doi.org\/10.1016\/j.bpobgyn.2021.02.005","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"key":"4896_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1148\/rg.2017160140","volume":"37","author":"AM Shaaban","year":"2017","unstructured":"Shaaban AM, Rezvani M, Haroun RR, Kennedy AM, Elsayes KM, Olpin JD, Salama ME, Foster BR, Menias CO (2017) Gestation Trophoblastic Disease: Clin Imaging Features RadioGraphics 37:681\u2013700. https:\/\/doi.org\/10.1148\/rg.2017160140","journal-title":"Gestation Trophoblastic Disease: Clin Imaging Features RadioGraphics"},{"key":"4896_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.humpath.2016.03.012","volume":"54","author":"M Stichelbout","year":"2016","unstructured":"Stichelbout M, Devisme L, Franquet-Ansart H, Massardier J, Vinatier D, Renaud F, Kerdraon O (2016) SALL4 expression in gestational trophoblastic tumors: a useful tool to distinguish choriocarcinoma from placental site trophoblastic tumor and epithelioid trophoblastic tumor. Hum Pathol 54:121\u2013126. https:\/\/doi.org\/10.1016\/j.humpath.2016.03.012","journal-title":"Hum Pathol"},{"key":"4896_CR27","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/biomedicines9101474","volume":"9","author":"C Collet","year":"2021","unstructured":"Collet C, Lopez J, Battail C, Allias F, Devouassoux-Shisheboran M, Patrier S, Lemaitre N, Hajri T, Massardier J, You B, Mallet F, Golfier F, Alfaidy N, Bolze P-A (2021) Transcriptomic Charact Postmolar Gestation Choriocarcinoma Biomedicines 9:1474. https:\/\/doi.org\/10.3390\/biomedicines9101474","journal-title":"Transcriptomic Charact Postmolar Gestation Choriocarcinoma Biomedicines"},{"key":"4896_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ygyno.2024.01.033","volume":"184","author":"L McNally","year":"2024","unstructured":"McNally L, Wu S, Hodges K, Oberley M, Wallbillich JJ, Jones NL, Herzog TJ, Thaker PH, Secord AA, Huang M (2024) Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets. Gynecol Oncol 184:111\u2013116. https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.033","journal-title":"Gynecol Oncol"},{"key":"4896_CR29","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/s0140-6736(17)32894-5","volume":"390","author":"E Ghorani","year":"2017","unstructured":"Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Carlson JW, Akarca A, Marafioti T, Quezada SA, Sarwar N, Seckl MJ (2017) Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet 390:2343\u20132345. https:\/\/doi.org\/10.1016\/s0140-6736(17)32894-5","journal-title":"Lancet"},{"key":"4896_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2019.08.024","volume":"121","author":"MC Choi","year":"2019","unstructured":"Choi MC, Oh J, Lee C (2019) Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. Eur J Cancer 121:94\u201397. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.024","journal-title":"Eur J Cancer"},{"issue":"1 22","key":"4896_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/S12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 2023 22(1 22):138\u2013. https:\/\/doi.org\/10.1186\/S12943-023-01827-6","journal-title":"Mol Cancer 2023"},{"key":"4896_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/IJGO.70275","volume":"171","author":"HYS Ngan","year":"2025","unstructured":"Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Braga A, Garrett A (2025) Diagnosis and management of gestational trophoblastic disease: 2025 update. Int J Gynecol Obstet 171:78\u201386. https:\/\/doi.org\/10.1002\/IJGO.70275","journal-title":"Int J Gynecol Obstet"},{"key":"4896_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bpobgyn.2021.01.004","volume":"74","author":"RA Fisher","year":"2021","unstructured":"Fisher RA, Maher GJ (2021) Genetics of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynecol 74:29\u201341. https:\/\/doi.org\/10.1016\/j.bpobgyn.2021.01.004","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"key":"4896_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5858\/arpa.2018-0234-ra","volume":"143","author":"P Hui","year":"2018","unstructured":"Hui P (2018) Gestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology. Arch Pathol Lab Med 143:65\u201374. https:\/\/doi.org\/10.5858\/arpa.2018-0234-ra","journal-title":"Arch Pathol Lab Med"},{"key":"4896_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/S00210-026-05202-2","author":"ABA Alshaikh","year":"2026","unstructured":"Alshaikh ABA, Al-kuraishy HM, Abdelaziz AM, Hepishy IM, Albar M, Batiha GE-S (2026) Targeting the GSK-3\u03b2\/mTOR axis: a novel pharmacological strategy for preeclampsia prevention and treatment, Naunyn. Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/S00210-026-05202-2","journal-title":"Schmiedebergs Arch Pharmacol"},{"key":"4896_CR36","doi-asserted-by":"publisher","first-page":"479249","DOI":"10.4061\/2011\/479249","volume":"2011","author":"M Medina","year":"2011","unstructured":"Medina M, Wandosell F (2011) Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimers Dis 2011:479249. https:\/\/doi.org\/10.4061\/2011\/479249","journal-title":"Int J Alzheimers Dis"},{"key":"4896_CR37","doi-asserted-by":"publisher","unstructured":"Stamos JL, Chu MLH, Enos MD, Shah N, Weis WI (2014) Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6, Elife 3 e01998. https:\/\/doi.org\/10.7554\/ELIFE.01998","DOI":"10.7554\/ELIFE.01998"},{"issue":"10","key":"4896_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-75020-w","volume":"10","author":"M Balasubramaniam","year":"2020","unstructured":"Balasubramaniam M, Mainali N, Bowroju SK, Atluri P, Penthala NR, Ayyadevera S, Crooks PA, Shmookler RJ, Reis (2020) Structural modeling of GSK3\u03b2 implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs. Sci Rep 2020 10(10):1. https:\/\/doi.org\/10.1038\/s41598-020-75020-w","journal-title":"Sci Rep 2020"},{"key":"4896_CR39","doi-asserted-by":"publisher","first-page":"10890","DOI":"10.1021\/BI100822Q","volume":"49","author":"I Buch","year":"2010","unstructured":"Buch I, Fishelovitch D, London N, Raveh B, Wolfson HJ, Nussinov R (2010) Allosteric Regulation of Glycogen Synthase Kinase 3\u03b2: A Theoretical Study. Biochemistry 49:10890\u201310901. https:\/\/doi.org\/10.1021\/BI100822Q","journal-title":"Biochemistry"},{"key":"4896_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.18632\/ONCOTARGET.1770","volume":"5","author":"A Goc","year":"2014","unstructured":"Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR (2014) Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget 5:775. https:\/\/doi.org\/10.18632\/ONCOTARGET.1770","journal-title":"Oncotarget"},{"key":"4896_CR41","doi-asserted-by":"publisher","unstructured":"Lei G, Xia Y, Johnson KM (2007) The Role of Akt-GSK-3\u03b2 Signaling and Synaptic Strength in Phencyclidine-Induced Neurodegeneration, Neuropsychopharmacology 2008 33:6 33. 1343\u20131353. https:\/\/doi.org\/10.1038\/sj.npp.1301511","DOI":"10.1038\/sj.npp.1301511"},{"key":"4896_CR42","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.urolonc.2015.05.006","volume":"33","author":"B Li","year":"2015","unstructured":"Li B, Thrasher JB, Terranova P (2015) Glycogen synthase kinase-3: A potential preventive target for prostate cancer management. Urologic Oncology: Seminars Original Investigations 33:456\u2013463. https:\/\/doi.org\/10.1016\/j.urolonc.2015.05.006","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"4896_CR43","doi-asserted-by":"publisher","first-page":"15384","DOI":"10.3389\/FNMOL.2011.00040","volume":"4","author":"O Kaidanovich-Beilin","year":"2011","unstructured":"Kaidanovich-Beilin O, Woodgett JR (2011) GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci 4:15384. https:\/\/doi.org\/10.3389\/FNMOL.2011.00040","journal-title":"Front Mol Neurosci"},{"key":"4896_CR44","doi-asserted-by":"publisher","unstructured":"Lim W, Yang C, Bazer FW, Song G (2016) Luteolin inhibits proliferation and induces apoptosis of human placental choriocarcinoma cells by blocking the PI3K\/AKT pathway and regulating sterol regulatory element binding protein activity. Biol Reprod 95. https:\/\/doi.org\/10.1095\/BIOLREPROD.116.141556\/2883513","DOI":"10.1095\/BIOLREPROD.116.141556\/2883513"},{"key":"4896_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.17305\/bjbms.2020.5036","volume":"21","author":"M Glibo","year":"2021","unstructured":"Glibo M, Serman A, Karin-Kujundzic V, Vlatkovic IB, Miskovic B, Vranic S, Serman L (2021) The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review. Bosn J Basic Med Sci 21:5\u201318. https:\/\/doi.org\/10.17305\/bjbms.2020.5036","journal-title":"Bosn J Basic Med Sci"},{"key":"4896_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/J.CANLET.2008.05.045","volume":"273","author":"J Luo","year":"2008","unstructured":"Luo J (2008) The Role of Glycogen Synthase Kinase 3\u03b2 (GSK3\u03b2) in Tumorigenesis and Cancer Chemotherapy. Cancer Lett 273:194. https:\/\/doi.org\/10.1016\/J.CANLET.2008.05.045","journal-title":"Cancer Lett"},{"key":"4896_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2174\/138920310791824093","volume":"11","author":"H Zhou","year":"2010","unstructured":"Zhou H, Huang S (2010) The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 11:409. https:\/\/doi.org\/10.2174\/138920310791824093","journal-title":"Curr Protein Pept Sci"},{"key":"4896_CR48","doi-asserted-by":"publisher","unstructured":"Tang J, Yang L, Guan F, Miller H, Camara NOS, James LK, Benlagha K, Kubo M, Heegaard S, Lee P, Lei J, Zeng H, He C, Zhai Z, Liu C (2023) The role of Raptor in lymphocytes differentiation and function. Front Immunol 14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1146628","DOI":"10.3389\/FIMMU.2023.1146628"},{"key":"4896_CR49","doi-asserted-by":"publisher","unstructured":"Chao LH, Avruch J (2019) Cryo-EM insight into the structure of MTOR complex 1 and its interactions with Rheb and substrates, F1000Res. 8. https:\/\/doi.org\/10.12688\/F1000RESEARCH.16109.1. F1000 Faculty Rev-14","DOI":"10.12688\/F1000RESEARCH.16109.1"},{"key":"4896_CR50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/BJ20070540","volume":"405","author":"LR Pearce","year":"2007","unstructured":"Pearce LR, Huang X, Boudeau J, Paw\u0142owski R, Wullschleger S, Deak M, Ibrahim AFM, Gourlay R, Magnuson MA, Alessi DR (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 405:513. https:\/\/doi.org\/10.1042\/BJ20070540","journal-title":"Biochem J"},{"key":"4896_CR51","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/J.JBC.2022.102288","volume":"298","author":"Z Yu","year":"2022","unstructured":"Yu Z, Chen J, Takagi E, Wang F, Saha B, Liu X, Joubert LM, Gleason CE, Jin M, Li C, Nowotny C, Agard D, Cheng Y, Pearce D (2022) Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt. J Biol Chem 298:102288. https:\/\/doi.org\/10.1016\/J.JBC.2022.102288","journal-title":"J Biol Chem"},{"key":"4896_CR52","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1038\/ONC.2010.139","volume":"29","author":"CA Sparks","year":"2010","unstructured":"Sparks CA, Guertin DA (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29:3733. https:\/\/doi.org\/10.1038\/ONC.2010.139","journal-title":"Oncogene"},{"key":"4896_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4161\/AUTO.7.7.15491","volume":"7","author":"EA Dunlop","year":"2011","unstructured":"Dunlop EA, Hunt DK, Acosta-Jaquez HA, Fingar DC, Tee AR (2011) ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy 7:737. https:\/\/doi.org\/10.4161\/AUTO.7.7.15491","journal-title":"Autophagy"},{"key":"4896_CR54","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1074\/jbc.M109.096222","volume":"285","author":"GA Soliman","year":"2010","unstructured":"Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC (2010) mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285:7866\u20137879. https:\/\/doi.org\/10.1074\/jbc.M109.096222","journal-title":"J Biol Chem"},{"key":"4896_CR55","doi-asserted-by":"publisher","first-page":"jcs224931","DOI":"10.1242\/JCS.224931","volume":"132","author":"CE Gleason","year":"2019","unstructured":"Gleason CE, Oses-Prieto JA, Li KH, Saha B, Situ G, Burlingame AL, Pearce D (2019) Phosphorylation at distinct subcellular locations underlies specificity in mTORC2-mediated activation of SGK1 and Akt. J Cell Sci 132:jcs224931. https:\/\/doi.org\/10.1242\/JCS.224931","journal-title":"J Cell Sci"},{"key":"4896_CR56","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751\/655399\/P\/AZD8055-IS-A-POTENT-SELECTIVE-AND-ORALLY","volume":"70","author":"CM Chresta","year":"2010","unstructured":"Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GCM, Guichard S, Pass M (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70:288\u2013298. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1751\/655399\/P\/AZD8055-IS-A-POTENT-SELECTIVE-AND-ORALLY","journal-title":"Cancer Res"},{"key":"4896_CR57","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099\/82997\/AM\/PRECLINICAL-CHARACTERIZATION-OF-OSI-027-A-POTENT","volume":"10","author":"SV Bhagwat","year":"2011","unstructured":"Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA (2011) Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: Distinct from rapamycin, Mol. Cancer Ther 10:1394\u20131406. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-1099\/82997\/AM\/PRECLINICAL-CHARACTERIZATION-OF-OSI-027-A-POTENT","journal-title":"Cancer Ther"},{"key":"4896_CR58","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1152\/physrev.00038.2014","volume":"95","author":"J Bockaert","year":"2015","unstructured":"Bockaert J, Marin P (2015) mTOR in Brain Physiology and Pathologies. Physiol Rev 95:1157\u20131187. https:\/\/doi.org\/10.1152\/physrev.00038.2014","journal-title":"Physiol Rev"},{"key":"4896_CR59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuroscience.2016.11.017","volume":"341","author":"K Switon","year":"2017","unstructured":"Switon K, Kotulska K, Janusz-Kaminska A, Zmorzynska J, Jaworski J (2017) Molecular neurobiology of mTOR. Neuroscience 341:112\u2013153. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.11.017","journal-title":"Neuroscience"},{"key":"4896_CR60","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/J.PHARMTHERA.2014.11.016","volume":"0","author":"E Beurel","year":"2014","unstructured":"Beurel E, Grieco SF, Jope RS (2014) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 0:114. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2014.11.016","journal-title":"Pharmacol Ther"},{"key":"4896_CR61","doi-asserted-by":"publisher","unstructured":"Sutherland C, Harrower R, Coats JT, Tauro S (2025) The enzyme glycogen synthase kinase-3 is associated with specific forms of oncogenesis; what more do we need to know to achieve clinical benefit? Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1880. 189365. https:\/\/doi.org\/10.1016\/J.BBCAN.2025.189365","DOI":"10.1016\/J.BBCAN.2025.189365"},{"key":"4896_CR62","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1101\/GAD.1110003","volume":"17","author":"K Inoki","year":"2003","unstructured":"Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829. https:\/\/doi.org\/10.1101\/GAD.1110003","journal-title":"Genes Dev"},{"key":"4896_CR63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","volume":"412","author":"J Huang","year":"2008","unstructured":"Huang J, Manning BD (2008) The TSC1\u2013TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179. https:\/\/doi.org\/10.1042\/BJ20080281","journal-title":"Biochem J"},{"key":"4896_CR64","doi-asserted-by":"publisher","first-page":"118635","DOI":"10.1016\/J.BBAMCR.2019.118635","volume":"1867","author":"C Evangelisti","year":"2020","unstructured":"Evangelisti C, Chiarini F, Paganelli F, Marmiroli S, Martelli AM (2020) Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer, Biochimica et Biophysica Acta (BBA) -. Mol Cell Res 1867:118635. https:\/\/doi.org\/10.1016\/J.BBAMCR.2019.118635","journal-title":"Mol Cell Res"},{"key":"4896_CR65","doi-asserted-by":"publisher","unstructured":"Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL, Brosius FC (2008) A GSK-3\/TSC2\/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 295. https:\/\/doi.org\/10.1152\/AJPCELL.00554.2007","DOI":"10.1152\/AJPCELL.00554.2007"},{"key":"4896_CR66","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/J.CELL.2022.04.013","volume":"185","author":"S Battaglioni","year":"2022","unstructured":"Battaglioni S, Benjamin D, W\u00e4lchli M, Maier T, Hall MN (2022) mTOR substrate phosphorylation in growth control. Cell 185:1814\u20131836. https:\/\/doi.org\/10.1016\/J.CELL.2022.04.013","journal-title":"Cell"},{"key":"4896_CR67","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.CCR.2007.07.006","volume":"12","author":"JD Gordan","year":"2007","unstructured":"Gordan JD, Thompson CB, Simon MC (2007) HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12:108. https:\/\/doi.org\/10.1016\/J.CCR.2007.07.006","journal-title":"Cancer Cell"},{"key":"4896_CR68","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/J.MOLCEL.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214. https:\/\/doi.org\/10.1016\/J.MOLCEL.2008.03.003","journal-title":"Mol Cell"},{"key":"4896_CR69","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/J.TIBS.2009.10.002","volume":"35","author":"D Wu","year":"2009","unstructured":"Wu D, Pan W (2009) GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 35:161. https:\/\/doi.org\/10.1016\/J.TIBS.2009.10.002","journal-title":"Trends Biochem Sci"},{"key":"4896_CR70","doi-asserted-by":"publisher","unstructured":"Chen CH, Shaikenov T, Peterson TR, Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK, Sarbassov DD (2011) ER stress inhibits mTORC2 and Akt signaling through GSK-3\u03b2-mediated phosphorylation of rictor. Sci Signal 4. https:\/\/doi.org\/10.1126\/SCISIGNAL.2001731;JOURNAL:JOURNAL:STKE;WEBSITE:WEBSITE:AAAS-SITE;WGROUP:STRING:PUBLICATION","DOI":"10.1126\/SCISIGNAL.2001731"},{"key":"4896_CR71","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/bj20150404","volume":"470","author":"C Stretton","year":"2015","unstructured":"Stretton C, Hoffmann TM, Munson MJ, Prescott A, Taylor PM, Ganley IG, Hundal HS (2015) GSK3-mediated raptor phosphorylation supports amino-acid-dependent mTORC1-directed signalling. Biochem J 470:207\u2013221. https:\/\/doi.org\/10.1042\/bj20150404","journal-title":"Biochem J"},{"key":"4896_CR72","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/pros.23836","volume":"79","author":"Y Sun","year":"2019","unstructured":"Sun Y, Ai J, Jin X, Liu L, Lin T, Xu H, Wei Q, Yang L (2019) IL-8 protects prostate cancer cells from GSK\u20103\u03b2\u2010induced oxidative stress by activating the mTOR signaling pathway. Prostate 79:1180\u20131190. https:\/\/doi.org\/10.1002\/pros.23836","journal-title":"Prostate"},{"key":"4896_CR73","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/J.MOLCEL.2006.09.019","volume":"24","author":"HH Zhang","year":"2006","unstructured":"Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 24:185. https:\/\/doi.org\/10.1016\/J.MOLCEL.2006.09.019","journal-title":"Mol Cell"},{"key":"4896_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35248\/2576-1471.19.4.203","volume":"4","author":"KM Hirschi","year":"2019","unstructured":"Hirschi KM, Tsai KYF, Edwards MM, Hall P, Mejia JF, Mejia CA, Reynolds PR, Arroyo JA (2019) The mTOR Family of Proteins and the Regulation of Trophoblast Invasion by Gas6. J Cell Signal 4:1\u20138. https:\/\/doi.org\/10.35248\/2576-1471.19.4.203","journal-title":"J Cell Signal"},{"key":"4896_CR75","doi-asserted-by":"publisher","first-page":"651692","DOI":"10.3389\/FONC.2021.651692\/BIBTEX","volume":"11","author":"S Ghuwalewala","year":"2021","unstructured":"Ghuwalewala S, Ghatak D, Das S, Roy S, Das P, Butti R, Gorain M, Nath S, Kundu GC, Roychoudhury S (2021) MiRNA-146a\/AKT\/\u03b2-Catenin Activation Regulates Cancer Stem Cell Phenotype in Oral Squamous Cell Carcinoma by Targeting CD24, Front. Oncol 11:651692. https:\/\/doi.org\/10.3389\/FONC.2021.651692\/BIBTEX","journal-title":"Oncol"},{"key":"4896_CR76","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann D, Park S, Hall MN (2018) mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 18:744\u2013757. https:\/\/doi.org\/10.1038\/s41568-018-0074-8","journal-title":"Nat Rev Cancer"},{"key":"4896_CR77","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1007\/s12035-017-0436-3","volume":"55","author":"A Koscielny","year":"2017","unstructured":"Koscielny A, Malik AR, Liszewska E, Zmorzynska J, Tempes A, Tarkowski B, Jaworski J (2017) Adaptor Complex 2 Controls Dendrite Morphology via mTOR-Dependent Expression of GluA2. Mol Neurobiol 55:1590\u20131606. https:\/\/doi.org\/10.1007\/s12035-017-0436-3","journal-title":"Mol Neurobiol"},{"key":"4896_CR78","doi-asserted-by":"publisher","unstructured":"Gozdz A, Nikolaienko O, Urbanska M, Cymerman IA, Sitkiewicz E, Blazejczyk M, Dadlez M, Bramham CR, Jaworski J (2017) GSK3\u03b1 and GSK3\u03b2 Phosphorylate Arc and Regulate its Degradation. Front Mol Neurosci 10. https:\/\/doi.org\/10.3389\/fnmol.2017.00192","DOI":"10.3389\/fnmol.2017.00192"},{"key":"4896_CR79","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1158\/0008-5472.CAN-13-2946","volume":"74","author":"J Koo","year":"2014","unstructured":"Koo J, Yue P, Gal AA, Khuri FR, Sun SY (2014) Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. Cancer Res 74:2555. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2946","journal-title":"Cancer Res"},{"key":"4896_CR80","doi-asserted-by":"publisher","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B (2021) Targeting PI3K\/Akt signal transduction for cancer therapy, Signal Transduct. Target Ther 6. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","DOI":"10.1038\/s41392-021-00828-5"},{"key":"4896_CR81","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR (2019) Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol 59:147\u2013160. https:\/\/doi.org\/10.1016\/j.semcancer.2019.05.012","journal-title":"Semin Cancer Biol"},{"key":"4896_CR82","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ijms22010173","volume":"22","author":"D Miricescu","year":"2020","unstructured":"Miricescu D, Totan A, Stanescu-Spinu I-I, Badoiu SC, Stefani C, Greabu M (2020) PI3K\/AKT\/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci 22:173. https:\/\/doi.org\/10.3390\/ijms22010173","journal-title":"Int J Mol Sci"},{"key":"4896_CR83","doi-asserted-by":"publisher","first-page":"820","DOI":"10.4161\/CC.27728","volume":"13","author":"M Sokolosky","year":"2014","unstructured":"Sokolosky M, Chappell WH, Stadelman K, Abrams SL, Davis NM, Steelman LS, McCubrey JA (2014) Inhibition of GSK-3\u03b2 activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. Cell Cycle 13:820. https:\/\/doi.org\/10.4161\/CC.27728","journal-title":"Cell Cycle"},{"key":"4896_CR84","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1242\/dev.137075","volume":"143","author":"JSL Yu","year":"2016","unstructured":"Yu JSL, Cui W (2016) Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination. Development 143:3050\u20133060. https:\/\/doi.org\/10.1242\/dev.137075","journal-title":"Development"},{"key":"4896_CR85","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","volume":"59","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani AS (2019) PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside, Semin. Cancer Biol 59:125\u2013132. https:\/\/doi.org\/10.1016\/j.semcancer.2019.07.009","journal-title":"Cancer Biol"},{"key":"4896_CR86","doi-asserted-by":"publisher","unstructured":"Lai X, Li Q, Wu F, Lin J, Chen J, Zheng H, Guo L (2020) Epithelial-Mesenchymal Transition and Metabolic Switching in Cancer: Lessons From Somatic Cell Reprogramming, Front. Cell Dev Biol 8. https:\/\/doi.org\/10.3389\/fcell.2020.00760","DOI":"10.3389\/fcell.2020.00760"},{"key":"4896_CR87","doi-asserted-by":"publisher","first-page":"e0185092","DOI":"10.1371\/JOURNAL.PONE.0185092","volume":"12","author":"M Lampa","year":"2017","unstructured":"Lampa M, Arlt H, He T, Ospina B, Reeves J, Zhang B, Murtie J, Deng G, Barberis C, Hoffmann D, Cheng H, Pollard J, Winter C, Richon V, Garcia-Escheverria C, Adrian F, Wiederschain D, Srinivasan L (2017) Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS ONE 12:e0185092. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0185092","journal-title":"PLoS ONE"},{"key":"4896_CR88","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/NCB2763;SUBJMETA","volume":"15","author":"CC Dibble","year":"2013","unstructured":"Dibble CC, Manning BD (2013) Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 15:555\u2013564. https:\/\/doi.org\/10.1038\/NCB2763;SUBJMETA","journal-title":"Nat Cell Biol"},{"key":"4896_CR89","doi-asserted-by":"publisher","first-page":"20177","DOI":"10.18632\/ONCOTARGET.3896","volume":"6","author":"C Peng","year":"2015","unstructured":"Peng C, Jia X, Xiong Y, Yin J, Li N, Deng Y, Luo K, Zhang Q, Wang C, Zhang Z, Zheng G, He Z, Peng C, Jia X, Xiong Y, Yin J, Li N, Deng Y, Luo K, Zhang Q, Wang C, Zhang Z, Zheng G, He Z (2015) in human tongue cancer. Oncotarget 6:20177\u201320189. https:\/\/doi.org\/10.18632\/ONCOTARGET.3896. The 14-3-3\u03c3\/GSK3\u03b2\/\u03b2-catenin\/ZEB1 regulatory loop modulates chemo-sensitivity","journal-title":"Oncotarget"},{"key":"4896_CR90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41389-019-0125-3","volume":"8","author":"N Li","year":"2019","unstructured":"Li N, Babaei-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, Domingo E, Tulchinsky E, Vries RGJ, Kerr D, Pan Y, He Y, Bates DO, Tomlinson I, Clevers H, Nateri AS (2019) An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncog 2019 8:38. https:\/\/doi.org\/10.1038\/s41389-019-0125-3","journal-title":"Oncog 2019"},{"key":"4896_CR91","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.ejca.2013.03.014","volume":"49","author":"H Zheng","year":"2013","unstructured":"Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, Shi M, Wang Z, Jiang B (2013) Glycogen synthase kinase-3 beta regulates Snail and \u03b2-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 49:2734\u20132746. https:\/\/doi.org\/10.1016\/j.ejca.2013.03.014","journal-title":"Eur J Cancer"},{"key":"4896_CR92","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.18240\/IJO.2018.07.08","volume":"11","author":"C Zhang","year":"2018","unstructured":"Zhang C, Su L, Huang L, Song ZY (2018) GSK3\u03b2 inhibits epithelial-mesenchymal transition via the Wnt\/\u03b2-catenin and PI3K\/Akt pathways. Int J Ophthalmol 11:1120. https:\/\/doi.org\/10.18240\/IJO.2018.07.08","journal-title":"Int J Ophthalmol"},{"key":"4896_CR93","doi-asserted-by":"publisher","first-page":"762817","DOI":"10.3389\/FONC.2021.762817\/FULL","volume":"11","author":"SO Imodoye","year":"2021","unstructured":"Imodoye SO, Adedokun KA, Muhammed AO, Bello IO, Muhibi MA, Oduola T, Oyenike MA (2021) Understanding the Complex Milieu of Epithelial-Mesenchymal Transition in Cancer Metastasis: New Insight Into the Roles of Transcription Factors. Front Oncol 11:762817. https:\/\/doi.org\/10.3389\/FONC.2021.762817\/FULL","journal-title":"Front Oncol"},{"key":"4896_CR94","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/J.CELREP.2015.07.016","volume":"12","author":"G Yang","year":"2015","unstructured":"Yang G, Murashige DS, Humphrey SJ, James DE (2015) A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. Cell Rep 12:937\u2013943. https:\/\/doi.org\/10.1016\/J.CELREP.2015.07.016","journal-title":"Cell Rep"},{"key":"4896_CR95","doi-asserted-by":"publisher","unstructured":"Bautista SJ (2021) Mitogenic and Metabolic signals regulate mTOR complex 1 function to control GSK3\u03b2 nuclear program. https:\/\/doi.org\/10.32920\/ryerson.14654061","DOI":"10.32920\/ryerson.14654061"},{"key":"4896_CR96","doi-asserted-by":"publisher","unstructured":"Ying X, Jing L, Ma S, Li Q, Luo X, Pan Z, Feng Y, Feng P (2015) GSK3\u03b2 mediates pancreatic cancer cell invasion in vitro via the CXCR4\/MMP-2 Pathway. Cancer Cell Int 15. https:\/\/doi.org\/10.1186\/s12935-015-0216-y","DOI":"10.1186\/s12935-015-0216-y"},{"key":"4896_CR97","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.7150\/thno.15083","volume":"6","author":"C Wang","year":"2016","unstructured":"Wang C, Jin H, Wang N, Fan S, Wang Y, Zhang Y, Wei L, Tao X, Gu D, Zhao F, Fang J, Yao M, Qin W (2016) Gas6\/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt\/GSK-3\u03b2\/\u03b2-catenin Signaling. Theranostics 6:1205\u20131219. https:\/\/doi.org\/10.7150\/thno.15083","journal-title":"Theranostics"},{"key":"4896_CR98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/BDI.13081","volume":"24","author":"SJ Tye","year":"2022","unstructured":"Tye SJ, Borreggine K, Price JB, Sutor SL, Cu\u00e9llar-Barboza AB, McElroy SL, Biernacka JM, Frye MA (2022) Dynamic insulin-stimulated mTOR\/GSK3 signaling in peripheral immune cells: Preliminary evidence for an association with lithium response in bipolar disorder. Bipolar Disord 24:39\u201347. https:\/\/doi.org\/10.1111\/BDI.13081","journal-title":"Bipolar Disord"},{"key":"4896_CR99","doi-asserted-by":"publisher","first-page":"77291","DOI":"10.18632\/oncotarget.12637","volume":"7","author":"LM Divine","year":"2016","unstructured":"Divine LM, Nguyen MR, Meller E, Desai RA, Arif B, Rankin EB, Bligard KH, Meyerson C, Hagemann IS, Massad M, Thaker PH, Hagemann AR, McCourt CK, Powell MA, Mutch DG, Fuh KC (2016) AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget 7:77291\u201377305. https:\/\/doi.org\/10.18632\/oncotarget.12637","journal-title":"Oncotarget"},{"key":"4896_CR100","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/S41374-021-00651-0","volume":"101","author":"S Wu","year":"2021","unstructured":"Wu S, Shao M, Zhang Y, Shi D (2021) Activation of RSK2 upregulates SOX8 to promote methotrexate resistance in gestational trophoblastic neoplasia. Lab Invest 101:1494\u20131504. https:\/\/doi.org\/10.1038\/S41374-021-00651-0","journal-title":"Lab Invest"},{"key":"4896_CR101","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ygyno.2020.01.013","volume":"157","author":"F Jun","year":"2020","unstructured":"Jun F, Peng Z, Zhang Y, Shi D (2020) Quantitative proteomic analysis identifies novel regulators of methotrexate resistance in choriocarcinoma. Gynecol Oncol 157:268\u2013279. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.013","journal-title":"Gynecol Oncol"},{"key":"4896_CR102","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/S10020-021-00300-8","volume":"27","author":"J Cui","year":"2021","unstructured":"Cui J, Guo Y, Wu H, Xiong J, Peng T (2021) Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K\/AKT\/mTOR signaling. Mol Med 27:38. https:\/\/doi.org\/10.1186\/S10020-021-00300-8","journal-title":"Mol Med"},{"key":"4896_CR103","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1159\/000484378","volume":"43","author":"MS Hakam","year":"2017","unstructured":"Hakam MS, Miranda-Sayago JM, Hayrabedyan S, Todorova K, Spencer PS, Jabeen A, Barnea ER, Fernandez N (2017) Preimplantation Factor (PIF) Promotes HLA-G,-E,-F,-C Expression in JEG-3 Choriocarcinoma Cells and Endogenous Progesterone Activity. Cell Physiol Biochem 43:2277\u20132296. https:\/\/doi.org\/10.1159\/000484378","journal-title":"Cell Physiol Biochem"},{"key":"4896_CR104","doi-asserted-by":"publisher","unstructured":"Persson G, Bork JBS, Isgaard C, Larsen TG, Bordoy AM, Bengtsson MS, Hviid TVF (2020) Cytokine stimulation of the choriocarcinoma cell line JEG-3 leads to alterations in the HLA-G expression profile. Cell Immunol 352. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104110","DOI":"10.1016\/j.cellimm.2020.104110"},{"key":"4896_CR105","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cellimm.2017.11.008","volume":"324","author":"WN Melsted","year":"2018","unstructured":"Melsted WN, Matzen SH, Andersen MH, Hviid TVF (2018) The choriocarcinoma cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-inflammatory cytokines through HLA-G. Cell Immunol 324:14\u201323. https:\/\/doi.org\/10.1016\/j.cellimm.2017.11.008","journal-title":"Cell Immunol"},{"key":"4896_CR106","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1126\/science.aag2553","volume":"356","author":"C Di Malta","year":"2017","unstructured":"Di Malta C, Siciliano D, Calcagni A, Monfregola J, Punzi S, Pastore N, Eastes AN, Davis O, De Cegli R, Zampelli A, Di Giovannantonio LG, Nusco E, Platt N, Guida A, Ogmundsdottir MH, Lanfrancone L, Perera RM, Zoncu R, Pelicci PG, Settembre C, Ballabio A (2017) Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth. Sci (1979) 356:1188\u20131192. https:\/\/doi.org\/10.1126\/science.aag2553","journal-title":"Sci (1979)"},{"key":"4896_CR107","doi-asserted-by":"publisher","first-page":"1486608","DOI":"10.3389\/FENDO.2024.1486608\/FULL","volume":"15","author":"L Liu","year":"2024","unstructured":"Liu L, Tang L, Chen S, Zheng L, Ma X (2024) Decoding the molecular pathways governing trophoblast migration and placental development; a literature review. Front Endocrinol (Lausanne) 15:1486608. https:\/\/doi.org\/10.3389\/FENDO.2024.1486608\/FULL","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4896_CR108","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/S43032-020-00324-1","volume":"28","author":"T Li","year":"2021","unstructured":"Li T, Wei S, Fan C, Tang D, Luo D (2021) Nesfatin-1 Promotes Proliferation, Migration and Invasion of HTR-8\/SVneo Trophoblast Cells and Inhibits Oxidative Stress via Activation of PI3K\/AKT\/mTOR and AKT\/GSK3\u03b2 Pathway. Reprod Sci 28:550\u2013561. https:\/\/doi.org\/10.1007\/S43032-020-00324-1","journal-title":"Reprod Sci"},{"key":"4896_CR109","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/AJI.12436","volume":"75","author":"SK Gupta","year":"2016","unstructured":"Gupta SK, Malhotra SS, Malik A, Verma S, Chaudhary P (2016) Cell Signaling Pathways Involved During Invasion and Syncytialization of Trophoblast Cells. Am J Reprod Immunol 75:361\u2013371. https:\/\/doi.org\/10.1111\/AJI.12436;CSUBTYPE:STRING:SPECIAL;PAGE:STRING:ARTICLE\/CHAPTER","journal-title":"Am J Reprod Immunol"},{"key":"4896_CR110","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.18632\/ONCOTARGET.2037","volume":"5","author":"JA Mccubrey","year":"2014","unstructured":"Mccubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D\u2019Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko Z, Cocco L, Martelli AM, Cervello M (2014) GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5:2881. https:\/\/doi.org\/10.18632\/ONCOTARGET.2037","journal-title":"Oncotarget"},{"key":"4896_CR111","doi-asserted-by":"publisher","first-page":"116685","DOI":"10.1016\/J.BIOPHA.2024.116685","volume":"175","author":"L Sun","year":"2024","unstructured":"Sun L, Xing J, Zhou X, Song X, Gao S (2024) Wnt\/\u03b2-catenin signalling, epithelial-mesenchymal transition and crosslink signalling in colorectal cancer cells. Biomed Pharmacother 175:116685. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.116685","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"4896_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, Zhou Z, Shu G, Yin G (2022) Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Therapy 2021 7(7):1. https:\/\/doi.org\/10.1038\/s41392-021-00762-6","journal-title":"Signal Transduct Target Therapy 2021"},{"key":"4896_CR113","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/1078-0432.CCR-23-1916","volume":"30","author":"BA Carneiro","year":"2024","unstructured":"Carneiro BA, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, Sahebjam S, Cervantes A, Koukol A, Mazar AP, Steeghs N, Kurzrock R, Giles FJ, Munster P (2024) Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3\u03b2 Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies, Clin. Cancer Res 30:522\u2013531. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1916","journal-title":"Cancer Res"},{"key":"4896_CR114","doi-asserted-by":"publisher","unstructured":"Pidkovka N, Belkhiri A (2023) Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target. Front Oncol 13:1079041. https:\/\/doi.org\/10.3389\/FONC.2023.1079041\/FULL","DOI":"10.3389\/FONC.2023.1079041\/FULL"},{"key":"4896_CR115","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1021\/ACS.JMEDCHEM.5B01273","volume":"59","author":"SH Myers","year":"2015","unstructured":"Myers SH, Brunton VG, Unciti-Broceta A (2015) AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. J Med Chem 59:3593\u20133608. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.5B01273","journal-title":"J Med Chem"},{"key":"4896_CR116","doi-asserted-by":"publisher","unstructured":"Park R, Coveler AL, Cavalcante L, Saeed A (2021) GSK-3\u03b2 in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties, Biology (Basel). 10:610. https:\/\/doi.org\/10.3390\/BIOLOGY10070610","DOI":"10.3390\/BIOLOGY10070610"},{"key":"4896_CR117","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/cells9061388","volume":"9","author":"T Domoto","year":"2020","unstructured":"Domoto T, Uehara M, Bolidong D, Minamoto T (2020) Glycogen Synthase Kinase 3\u03b2 in Cancer Biology and Treatment. Cells 9:1388. https:\/\/doi.org\/10.3390\/cells9061388","journal-title":"Cells"},{"key":"4896_CR118","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1200\/JCO.2012.43.1817","volume":"31","author":"C Alifrangis","year":"2013","unstructured":"Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, Seckl MJ (2013) EMA\/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 31:280\u2013286. https:\/\/doi.org\/10.1200\/JCO.2012.43.1817","journal-title":"J Clin Oncol"},{"key":"4896_CR119","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/S12672-025-03707-5","volume":"16","author":"F Erfiandi","year":"2025","unstructured":"Erfiandi F, Waluyo ST, Sibarani CNR, Winarno GNA, Haniah AS, Adrianto N (2025) Strategies for managing EMA\/CO resistant in gestational trophoblastic neoplasia a systematic review and meta analysis. Discover Oncol 16:1879. https:\/\/doi.org\/10.1007\/S12672-025-03707-5","journal-title":"Discover Oncol"},{"key":"4896_CR120","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/J.BBRC.2013.09.130","volume":"440","author":"Q Li","year":"2013","unstructured":"Li Q, Song XM, Ji YY, Jiang H, Xu LG (2013) The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem Biophys Res Commun 440:701\u2013706. https:\/\/doi.org\/10.1016\/J.BBRC.2013.09.130","journal-title":"Biochem Biophys Res Commun"},{"key":"4896_CR121","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4161\/AUTO.6.4.11671","volume":"6","author":"P Sini","year":"2010","unstructured":"Sini P, James D, Chresta C, Guichard S (2010) Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy 6:553\u2013554. https:\/\/doi.org\/10.4161\/AUTO.6.4.11671","journal-title":"Autophagy"},{"key":"4896_CR122","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1095\/biolreprod.116.141556","volume":"95","author":"W Lim","year":"2016","unstructured":"Lim W, Yang C, Bazer FW, Song G (2016) Luteolin Inhibits Proliferation and Induces Apoptosis of Human Placental Choriocarcinoma Cells by Blocking the PI3K\/AKT Pathway and Regulating Sterol Regulatory Element Binding Protein Activity. Biol Reprod 95:82. https:\/\/doi.org\/10.1095\/biolreprod.116.141556","journal-title":"Biol Reprod"},{"key":"4896_CR123","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.8123","author":"Z Li","year":"2017","unstructured":"Li Z, Dong H, Li M, Wu Y, Liu Y, Zhao Y, Chen X, Ma M (2017) Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K\/Akt\/mTOR signaling pathway. Mol Med Rep. https:\/\/doi.org\/10.3892\/mmr.2017.8123","journal-title":"Mol Med Rep"},{"key":"4896_CR124","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/ptr.6780","volume":"34","author":"GA Borges","year":"2020","unstructured":"Borges GA, Elias ST, Amorim B, de Lima CL, Della Coletta R, Castilho RM, Squarize CH, Guerra ENS (2020) Curcumin downregulates the <\u2009scp>PI3K\u2013AKT\u2013mTOR pathway and inhibits growth and progression in head and neck cancer cells. Phytother Res 34:3311\u20133324. https:\/\/doi.org\/10.1002\/ptr.6780","journal-title":"Phytother Res"},{"key":"4896_CR125","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","volume":"103","author":"J Yang","year":"2018","unstructured":"Yang J, Pi C, Wang G (2018) Inhibition of PI3K\/Akt\/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother 103:699\u2013707. https:\/\/doi.org\/10.1016\/j.biopha.2018.04.072","journal-title":"Biomed Pharmacother"},{"key":"4896_CR126","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1002\/jcb.27654","volume":"120","author":"J Jiang","year":"2018","unstructured":"Jiang J, Pi J, Jin H, Cai J (2018) Oridonin-induced mitochondria\u2010dependent apoptosis in esophageal cancer cells by inhibiting PI3K\/AKT\/mTOR and Ras\/Raf pathways. J Cell Biochem 120:3736\u20133746. https:\/\/doi.org\/10.1002\/jcb.27654","journal-title":"J Cell Biochem"},{"key":"4896_CR127","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.12659\/msm.915387","volume":"25","author":"C Li","year":"2019","unstructured":"Li C, Zhou Y, Cai Y, Shui C, Liu W, Wang X, Jiang J, Zeng D, Gui C, Sun R (2019) Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)\/PI3K\/AKT Signaling Pathway. Med Sci Monit 25:5054\u20135061. https:\/\/doi.org\/10.12659\/msm.915387","journal-title":"Med Sci Monit"},{"key":"4896_CR128","doi-asserted-by":"publisher","first-page":"e70220","DOI":"10.1002\/CNR2.70220;CTYPE:STRING:JOURNAL","volume":"8","author":"J Zhang","year":"2025","unstructured":"Zhang J, Guo J, Qian Y, Yu L, Ma J, Gu B, Tang W, Li Y, Li H, Wu W (2025) Quercetin Induces Apoptosis Through Downregulating P4HA2 and Inhibiting the PI3K\/Akt\/mTOR Axis in Hepatocellular Carcinoma Cells: An In Vitro Study. Cancer Rep 8:e70220. https:\/\/doi.org\/10.1002\/CNR2.70220;CTYPE:STRING:JOURNAL","journal-title":"Cancer Rep"},{"key":"4896_CR129","doi-asserted-by":"publisher","first-page":"1357980","DOI":"10.3389\/FONC.2024.1357980","volume":"14","author":"M Peterson","year":"2024","unstructured":"Peterson M, Kolin DL, Konstantinopoulos PA (2024) Case report: Response to everolimus in a patient with platinum resistant, high grade serous ovarian carcinoma with biallelic TSC2 inactivation. Front Oncol 14:1357980. https:\/\/doi.org\/10.3389\/FONC.2024.1357980","journal-title":"Front Oncol"},{"key":"4896_CR130","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/S40164-018-0103-Z","volume":"7","author":"PB Johnston","year":"2018","unstructured":"Johnston PB, Pinter-Brown LC, Warsi G, White K, Ramchandren R (2018) Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. Exp Hematol Oncol 7:12. https:\/\/doi.org\/10.1186\/S40164-018-0103-Z","journal-title":"Exp Hematol Oncol"},{"key":"4896_CR131","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/J.YGYNO.2021.12.031","volume":"164","author":"BM Slomovitz","year":"2022","unstructured":"Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL (2022) A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol 164:481\u2013491. https:\/\/doi.org\/10.1016\/J.YGYNO.2021.12.031","journal-title":"Gynecol Oncol"},{"key":"4896_CR132","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ygyno.2020.05.042","volume":"158","author":"PA Bolze","year":"2020","unstructured":"Bolze PA, Lopez J, Allias F, Hajri T, Patrier S, Devouassoux-Shisheboran M, Massardier J, You B, Golfier F, Mallet F (2020) Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy. Gynecol Oncol 158:785\u2013793. https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.042","journal-title":"Gynecol Oncol"},{"issue":"9","key":"4896_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"XP Duan","year":"2024","unstructured":"Duan XP, Qin BD, Jiao XD, Liu K, Wang Z, Zang YS (2024) New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Therapy 2024 9(9):1. https:\/\/doi.org\/10.1038\/s41392-024-01760-0","journal-title":"Signal Transduct Target Therapy 2024"},{"key":"4896_CR134","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/S13023-025-04048-W","volume":"20","author":"W Khazen","year":"2025","unstructured":"Khazen W, Corriol-Rohou S, Evangelista T, Valent A, Abbas S, Nissan X, Mejat A (2025) Basket trials in rare diseases: a systematic review of current practices, methodological challenges, and future directions. Orphanet J Rare Dis 20:578. https:\/\/doi.org\/10.1186\/S13023-025-04048-W","journal-title":"Orphanet J Rare Dis"},{"key":"4896_CR135","doi-asserted-by":"publisher","first-page":"1687805","DOI":"10.3389\/FPHAR.2025.1687805","volume":"16","author":"B Muttiah","year":"2026","unstructured":"Muttiah B, Abdullah NAH (2026) Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential. Front Pharmacol 16:1687805. https:\/\/doi.org\/10.3389\/FPHAR.2025.1687805","journal-title":"Front Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04896-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04896-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04896-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:07:01Z","timestamp":1778591221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04896-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4896"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04896-8","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}